financetom
Business
financetom
/
Business
/
Tesla's Chinese Rival Looks All Set To Soar Amid Strong Domestic EV Tailwinds: Momentum Score Surges
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla's Chinese Rival Looks All Set To Soar Amid Strong Domestic EV Tailwinds: Momentum Score Surges
Sep 23, 2025 2:44 AM

A key Chinese Tesla Inc. ( TSLA ) competitor in the EV space is seeing a surge in its Momentum score in Benzinga’s Edge Stock Ranking, with big gains in just over a week.

Surge In Momentum Scores

In Benzinga's Edge Stock Rankings, stocks are ranked as a percentile based on Quality, Value, Growth and Momentum. The Momentum score essentially takes into account price movements and volatility of a particular stock across several different time frames, before ranking them individually as a percentile against all other stocks.

See Also: 2 Restaurant Chain Stocks That Are Getting Increasingly Cheaper: Value Scores Hit Fresh High

Over the past week, a Chinese automotive startup has been surging in Benzinga’s Momentum rankings, indicating heightened interest and volume in the stock.

Growing Optimism In China’s Tech And EV Sectors

The stock in question is automaker Nio Inc. ( NIO ) , which witnessed a surge in Momentum from 46.79 to 86.08 within the span of a week. The stock is up 13.46% over the past month, and 51.87% year-to-date, primarily driven by the resurgence in optimism surrounding China’s tech and EV sectors.

Besides this, the company recently raised $1.16 billion through an equity offering, with proceeds earmarked for R&D, battery swap infrastructure, and vehicle platform development.

The capital infusion appears to have reassured investors, especially in light of NIO's ongoing efforts to expand delivery capacity and roll out new models. One such development is the shipment of the company's ES8 SUVs to dealerships ahead of launch, signaling progress on the product execution front.

The stock was down 6.24% on Monday, closing at $6.91, and is down another 0.87% in pre-market. According to Benzinga’s Edge Stock Rankings, the stock scores well on Momentum, but does poorly on Growth, with a favorable price trend in the short, medium and long terms. Click here for deeper insights into the stock, its peers and competitors.

Read More:

3 Apparel Manufacturer Stocks That Are Beginning To Wear Out: Steep Decline In Growth Scores

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved